Characterization of the New Cytomygalovirus Immunoglobulin Preparation for Intravenous Use
On the basis of the occurrence of antibodies against cytomegalovirus, the incidence of this infection in Europe and North America is about 60–70% of the total population. CMV infections are, in most cases, clinically inapparent. Alterations in the immunological defence system, caused for example by pregnancy, the presence of malignant disease, immunosuppressive or cytostatic therapy, as well as by massive transfusions of blood, are the commonest causes of an increased incidence of CMV infection, combined with a high rate of clinically overt illness (Fig. 1). This applies both to primary CMV infections as well as to the reactivation of latent virus in the body.
Unable to display preview. Download preview PDF.
- 1.Condie RM, Hall BL, Howard RJ, Fry D, Simmons RL, Najarian JS. Treatment of life-threatening infections in renal transplant recipients with high-dose intravenous human IgG. Transplant Proc II 1979; 1: 66–8.Google Scholar
- 3.O’Reilly RJ, Riech L, Gold J, et al. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: Preliminary results. IX. Intern Congress of the Transplant Society, Brighton 1982 (abstract).Google Scholar
- 6.Stephan W, Dichtelmiiller H. Beta-propiolacton als sterilisierendes Agens bei der Herstellung eines inträvenosen Immunoglobulin-Präparates. Arzneim Forsch/Drug Res 1983; 33: 1230–1.Google Scholar